Second quarter 2023 results
Second quarter 2023 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.
14:30 -16:00 CET | 8:30am – 10am EST
Featuring
Paul Hudson
Chief Executive Officer
Jean-Baptiste de Chatillon
Chief Financial Officer
Bill Sibold
Specialty Care
Olivier Charmeil
General Medicines
Dietmar Berger
Global Head of R&D ad interim
Thomas Triomphe
Vaccines
Julie van Ongevalle
Consumer Healthcare
Roy Papatheodorou
General Counsel
Highlights
We delivered another solid quarter of growth and are excited by the momentum of our R&D pipeline, with a strong flow of positive readouts and regulatory achievements that match our best-in-class ambitions.
Paul Hudson
Chief Executive Officer